<DOC>
	<DOC>NCT02554955</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function. The anticipated time on study treatment is 6 months, and the target sample size is 44 individuals.</brief_summary>
	<brief_title>A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants</brief_title>
	<detailed_description />
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Adult participants greater than 18 years of age Single organ (heart) transplant recipients At risk for posttransplant renal dysfunction Previous organ transplant Previous treatment with mycophenolate mofetil, daclizumab or sirolimus Positive for human immunodeficiency virus (HIV) infection History of malignancy within the last 5 years, except localized and treated skin cancer, treated and without evident relapse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>